Table 1.
Baseline characteristics.
| Dendritic cell vaccinated stage III melanoma patients N = 97(%) | ||
|---|---|---|
| Sex | ||
| Male | 60 | (62) |
| Female | 37 | (38) |
| Age, years | ||
| Mean (range) | 50.6 | (22–79) |
| Age in categories, years | ||
| 21–30 | 4 | (4) |
| 31–40 | 19 | (20) |
| 41–50 | 23 | (24) |
| 51–60 | 31 | (32) |
| ≥61 | 20 | (21) |
| Breslow thickness primary melanoma, mm | ||
| ≤1.0 | 7 | (7) |
| 1.01–2.0 | 26 | (27) |
| 2.01–4.0 | 25 | (26) |
| >4.0 | 31 | (32) |
| No primary/unknown | 8 | (8) |
| Ulceration of primary melanoma | ||
| Absent | 68 | (70) |
| Present | 29 | (30) |
| Histological type melanoma | ||
| Superficial spreading | 54 | (56) |
| Nodular | 22 | (23) |
| Acral lentiginous | 1 | (1) |
| Lentigo maligna | 1 | (1) |
| Spitzoid | 2 | (2) |
| No primary/unknown | 17 | (18) |
| N stage at inclusion | ||
| N1a | 24 | (25) |
| N1b | 24 | (25) |
| N2a | 5 | (5) |
| N2b | 14 | (14) |
| N3 | 30 | (31) |
| AJCC pathological stage | ||
| IIIA | 21 | (22) |
| IIIB | 34 | (35) |
| IIIC | 42 | (43) |
| Adjuvant radiotherapya | ||
| No | 91 | (94) |
| Yes | 6 | (6) |
a
Adjuvant radiotherapy was given after the apheresis, but before the first vaccination.